Increasing the sensitivity of the rodent uterotrophic assay to estrogens, with particular reference to bisphenol A. by Ashby, J
Environmental Health Perspectives • VOLUME 109 | NUMBER 11 | November 2001 1091
Increasing the Sensitivity of the Rodent Uterotrophic Assay to Estrogens,
with Particular Reference to Bisphenol A
John Ashby
Syngenta Central Toxicology Laboratory, Macclesﬁeld, Cheshire, UK
The rodent uterotrophic assay is currently
being validated as a regulatory screening assay
for estrogenicity by the Organisation for
Economic Co-operation and Development
(OECD) (1). The assay determines growth
of the uterus gravimetrically in response to
administration of a chemical to either sexu-
ally immature or ovariectomized rodents.
Historically, both rats and mice and a variety
of routes of administration of test chemicals
have been used for the assay. I have assumed
here that substantial equivalence exists
between the different ways of conducting the
assay, but individual cases of one species of
rodent being more sensitive than the other
can be anticipated, just as the use of different
routes of administration may modulate some
assay responses due to differences in the
adsorbtion, distribution, metabolism, and
excretion of the chemical. In fact, these vari-
ables, and their possible influence on the
routine use of the uterotrophic assay, are
being considered in phase II of the OECD
validation study (1). 
A positive uterotrophic response is not, of
itself, an adverse toxicologic response. Rather,
it provides information on the ability of a
chemical to inﬂuence an estrogen-responsive
process in living animals. Recently, several
research groups evaluated whether the sensi-
tivity of the assay can be increased by the use
of surrogate markers, such as changes in the
expression of estrogen-regulated uterine
genes, advancement of vaginal opening in
immature animals, or changes in uterine
pathology or cellular growth. The objective
of these efforts is that the lowest-effective-
dose level (LOEL) of an active agent may be
reduced by increasing the sensitivity of the
assay, which in some cases may result in
activity for an agent that was previously
found to be inactive. Underlying these efforts
is the assumption that a cascade of molecular
and biological events leads to uterine growth
and that any of the presumed precursor
events can act as surrogates for an increase in
uterine weight. In this paper I explore three
issues: a) whether such surrogate markers are,
in fact, more sensitive than gravimetric analy-
sis of the uterus, b) whether they are needed
to predict the estrogenicity of chemicals, and
c) whether they are reliable and suitable for
general adoption. 
One difficulty with these issues is that
few investigators have rigorously compared
markers of uterine growth with changes in
uterine weight in the same study. In a recent
study, Freyberger et al. (2) reevaluated the
reported lack of uterotrophic activity of
resveratrol (3) and failed to demonstrate any
activity using the variety of markers of uter-
ine growth evaluated. However, the largest
database available relates to multiple evalua-
tions of bisphenol A (BPA). Most of these
studies were initiated in an attempt to recon-
cile reports of the weak uterotrophic activity
of BPA and its lack of effects in multigenera-
tional rodent studies, with conflicting
reports of its ability to influence the sexual
development and maturation of rodents at
much lower doses (4,5). In particular, in a
recent evaluation of BPA, Markey et al. (5)
noted that the induction of premature vagi-
nal opening by BPA occurred at a dose
1,000 times lower than the dose at which a
uterotrophic response was seen. This led
these investigators to question the usefulness
of the uterotrophic assay. In this paper, I will
discuss many of the available BPA assays in
the uterus, beginning with the rat studies.
BPA has been established as a weak
uterotrophic agent in most of the studies
conducted in the rat (6–12). The ﬁrst study
in which surrogate markers were evaluated
was by Gould et al. (10), who reported that
orally administered BPA gave a negative
uterotrophic response in the immature rat
when tested to the limit of its solubility in
oil (150 mg/kg/day; Figure 1). However,
Gould et al. (10) observed changes in the
levels of estrogen-responsive uterine protein
peroxidase (Per) and the progesterone recep-
tor (PR) at several doses of BPA that were
evaluated. The combined data reported by
Gould et al. (10), together with the positive
uterotrophic activity of BPA in immature
rats concomitantly reported by Ashby and
Tinwell (9), are shown in Figure 1. The two
sets of uterotrophic data are probably consis-
tent with each other and form part of the
same dose–response relationship. The
increases in Per and PR seen at the higher
doses also seem to be a part of the same
uterotrophic dose response, but the induc-
tion patterns of these two proteins at lower
doses of BPA are ambiguous. First, the Per
activity shows a signiﬁcant reduction at the
lowest dose tested, in contrast to the
increases seen at the upper two doses, an
effect that may be due to chance. Second,
the induction of PR was significantly ele-
vated across a plateau embracing the five
lower doses of BPA evaluated. This absence
of a dose response for PR induction is inex-
plicable and raises questions as to its biologi-
cal significance and its no-observed-effect
level (NOEL). 
Steinmetz et al. (11) studied the ability
of BPA to increase hyperplasia and the
expression of c-fos in the uterus of the rat
after the intraperitoneal injection of BPA.
The NOELs for increases in uterine weight
and uterine hyperplasia (both determined 20
hr after the final administration of BPA)
were 100 mg/kg and 30 mg/kg, respectively;
the NOEL for c-fos expression was 3 mg/kg
(determined 2 hr after the ﬁnal administra-
tion of BPA). However, c-fos induction suf-
fers from being a nonspecific marker, as
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The gravimetric uterotrophic assay is currently the most well-established, short-term rodent estro-
genicity assay. Increasing attention is being paid to the extent to which use of morphometric or
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Commentaryshown by its failure to correlate with the
strain-specific induction of vaginal DNA
synthesis in BPA-exposed rats (13). More
recently, Laws et al. (6) reported positive
uterotrophic activity for doses of 200 and
400 mg/kg BPA (oral gavage) in immature
rats and a negative uterotrophic response for
100 mg/kg BPA. Laws et al. (6) also
reported no advances in vaginal opening in
immature rats exposed to doses of 100–400
mg/kg BPA. These data indicate that
uterotrophic activity for BPA can consis-
tently be detected in the rat only at doses
> 100 mg/kg and that effects on uterine c-fos
gene expression and peroxidase activity can
be detected at doses up to approximately 30
times lower. However, the reproducibility,
consistency, and biological significance of
the changes in effects of c-fos expression and
peroxidase activity remain to be established. 
In the ﬁrst uterotrophic assay of BPA in
the mouse, Coldham et al. (14) used imma-
ture CFLP mice and subcutaneous (sc) injec-
tions of the test agent; results were negative.
However, four additional and more exten-
sive mouse uterotrophic assays of BPA were
reported in isolation of each other over the
past year (5,15–17). Papaconstantinou et al.
(15) used ovariectomized B6C3F1 mice and
reported results for the dose range of approx-
imately 1–400 mg/kg BPA (sc injection;
doses expressed per mouse, with no body
weights provided). Positive uterotrophic
activity was observed at ≥ 40 mg/kg BPA. At
the uterotrophic dose of 200 mg/kg BPA,
uterine stromal and myometrial thickness
and epithelial cell height were increased (15).
However, the absence of data for these
histopathologic parameters at the lower
doses precludes assessment of their sensitiv-
ity relative to changes in uterine weight. In
the earliest of the three immature mouse
uterotrophic assays, Mehmood et al. (16)
treated CD-1 mice with a range of potent
synthetic estrogens and compared the
uterotrophic responses of the mice to the
induced changes in the expression of lacto-
ferrin and Per and in the incorporation of
bromodeoxyuridine (BrdU) into the luminal
epithelium of the uterus. For most of these
reference estrogens, the cellular end points
studied were of similar or greater sensitivity
than changes in uterine weight. However,
Mehmood et al. (16) concluded that BrdU
labeling of the stromal myometrium is difﬁ-
cult to quantify and that it is probably not a
practical assay end point. In addition, they
noted occasional unexpected increases in
BrdU labeling in the uterus of some of their
control animals, which they suggested may
reflect the early onset of puberty. They
endorsed the use of lactoferrin as a practical
assay end point, but presented only pooled
data for lactoferrin induction, making it
impossible to assess the data statistically.
Nonetheless, this marker seemed to have
similar sensitivity to the gravimetric end
point (16). Mehmood et al. (16) also studied
orally administered BPA over the dose range
0.01–1,000 mg/kg/day and concluded that
it failed to a) increase uterine weight, b)
reproducibly alter the level of expression of
Per and lactoferrin, or c) increase BrdU
incorporation into the uterus.
In the second immature mouse utero-
trophic assays of BPA reported, Tinwell et
al. (17) described the results of nine inde-
pendent uterotrophic assays in the AP mouse
covering the dose range 0.02–300 mg/kg
BPA (eight assays using sc injection and one
using oral gavage). The reason so many
experiments were performed was that signs
of weak uterotrophic activity were observed
for BPA at some dose levels, but in general,
these observations were not confirmed in
repeat experiments. In three of the experi-
ments, uterine cell height was assessed and
BrdU labeling of the uterus was performed;
the results of these studies are shown in
Table 1. Study 8 (Table 1) showed statisti-
cally significant, but weak, uterotrophic
activity for a dose of 5 mg/kg BPA (21%
increase in uterine weight) and for doses of
≥ 50 mg/kg BPA (up to 26% increases), but
not at 10 mg/kg BPA (8% increase). There
was some support for these activities from
the BrdU-labeling data, but not from the
cell height data. Increases in BrdU labeling
were observed for 200 and 300 mg/kg BPA
in the oral study (study 9; Table 1), but in
the absence of a significant uterotrophic
response (maximum increase in uterine
weight of 14% at 300 mg/kg BPA). Tinwell
et al (17) observed an isolated, weak, but sta-
tistically significant increase in the BrdU
labeling index of the stromal layer for 5
mg/kg BPA (Study 9; Table 1). Overall,
these mouse data for BPA (15–17) do not
support the measurement of uterine cellular
compartment dimensions or labeling indices
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Figure 1. Data for BPA in the rat uterus as reported by Gould et al. (10) and Ashby and Tinwell (9). 
*Statistically signiﬁcantly different from control values. 
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01 1 0 100as providing major improvements in the sen-
sitivity of the uterotrophic assay for BPA.
The most recent immature mouse
uterotrophic assay of BPA was reported by
Markey et al. (5) in the CD-1 mouse. The
chemical was delivered by osmotic pumps
implanted into the subcutis; this method was
estimated to yield exposures of between 0.1
and 100 mg/kg/day BPA (data summarized
in Figure 2 and Table 2). The authors con-
cluded that although BPA was only active in
the uterotrophic assay at the 100 mg/kg dose,
it induced cellular and other changes at lower
doses. There was general concordance
between the gravimetric uterotrophic data
and the changes in epithelial cell height,
luminal and glandular labeling [determined
using proliferating cell nuclear antigen
(PCNA), a method that the authors believe is
not as accurate as BrdU], and lactoferrin
expression over the dose range of 75–100
mg/kg BPA; isolated morphometric effects
were observed at 5 mg/kg BPA (Figure 2,
Table 2). 
Markey et al. (5) also reported an advance
in the mean day of vaginal opening for the
lowest and the highest doses of BPA evaluated
(Figure 2, Table 2); however, these effects are
probably not biologically signiﬁcant. First, the
group sizes for were low (five and six mice
observed, respectively). Second, a surprisingly
high proportion of the control mice had open
vaginas at the end of the study (19/48; 40%)
and the mean control uterine weights were
unusually high (19 mg), both of which may
be explained by the study starting at the
unusually late time of postnatal day 23.
Together, these data indicate that the mice
used by Markey et al. (5) were entering
puberty by the end of their study, which
weakens the conclusions drawn. Further, if
BPA did not advance vaginal opening in the
mouse, it would be consistent with the
absence of such an effect in the rat (6). Thus,
none of the effects that Markey et al. (5)
reported for BPA in the mouse uterus give
unequivocal and consistent indications that
the surrogate markers used were more sensi-
tive indicators of estrogencity than are
changes in uterine weight.
The ﬁrst issue I raised in this paper was
whether the uterine cellular or molecular sur-
rogate markers currently under study can pro-
vide a more sensitive indicator of the
estrogenicity of chemicals than do changes in
uterine weight. This remains an important
area of investigation; however, further
detailed dose–response studies using reference
estrogens such as diethylstilbestrol and genis-
tein will be needed before this question can be
answered. The data discussed herein for
resveratrol and BPA do not support the need
for surrogate markers, but a larger database is
required. The fact that all of the surrogates
evaluated to date are expensive and cumber-
some increases the need to answer this ques-
tion unequivocally. 
The second issue I raised was the rele-
vance and need for surrogate markers. One
way to assess this is to compare the uterine
tissue responses to a chemical to the chemi-
cal’s activity in multigenerational studies. In
the case of BPA, no reproductive or develop-
mental effects were observed at doses < 500
mg/kg BPA in dietary or gavage multigener-
ational studies in the rat (18,19), which
accords well with the weak uterotrophic
activity of BPA in the rat. However, compar-
ing the LOEL of BPA in the uterotrophic
assay (approximately 100 mg/kg) to reports
of its endocrine activity at much lower doses
(4,5) shows that there is a need for poten-
tially more sensitive surrogates for the
uterotrophic assay, a need not met by the
markers considered in this analysis. In the
case of BPA, therefore, the surrogate markers
evaluated have not fulﬁlled their promise. 
The third issue I raised was the reliabil-
ity and practicality of the surrogate markers
currently under study. As a general point,
Commentary • Increasing the sensitivity of the rodent uterotrophic assay
Environmental Health Perspectives • VOLUME 109 | NUMBER 11 | November 2001 1093
Table 1. Data for three mouse uterotropic assays of BPA in which markers of uterine growth were also
evaluated. 
Experiment Assay BPA (mg/kg)
No. parameter 0.02 0.2 0.5 1 5 10 50 100 200 300
6 (sc) Uterine blotted wt – – **
Epithelial LI – – **
Glandular LI – – **
Stromal LI – – **
Epithelial height – – –
Endometrial height – – –
8 (sc) Uterine blotted wt – – – ** – ** ** **
Epithelial LI – – – * – ** ** **
Glandular LI – – – – – ** * **
Stromal LI – – – – – * – –
Epithelial height – – – – – – – *
Endometrial height – – – – – – – –
9 (oral) Uterine blotted wt – – – – – – – –
Epithelial LI – – – – – – ** **
Glandular LI – – – – – – – **
Stromal LI – – * – – – ** **
Epithelial height – – – – – – – –
Endometrial height – – – – – – – –
Abbreviations: –, no change; LI, labeling index as measured in BrdU-stained cells; wt, weight. Empty boxes represent values
not determined. Data from Tinwell et al. (17). 
*p < 0.05; **p < 0.01. 
Figure 2. Mouse body weight and uterine wet weight data for BPA as reported by Markey et al. (5). 
*Statistically signiﬁcant changes.
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Table 2. Mouse uterine data for BPA as reported by Markey et al. (5).
BPA (mg/kg)
Parameter 0.1 0.5 1 5 50 75 100
Vaginal opening + – – – – – +
Epithelial cell height – – – + – + +
Lamina propria area – – – + – – –
Luminal and glandular epithelial LI – – – – – + +
Lactoferrin expression – – – – – + +
Abbreviations: –, no change; +, change; LI, labeling index (PCNA).technical considerations complicate the use
of many of the markers. For example,
although protein levels (such as for PR using
Western blotting or competitive binding)
can be determined using uterine tissue col-
lected up to 24 hr after the ﬁnal administra-
tion of the test agent (as is usual with the
uterotrophic assay), the optimum time of
determination of mRNA levels will be inﬂu-
enced by the half-lives of individual mes-
sages; this may be as early as 2 hr after
dosing (11,13). In fact, there may be no sin-
gle optimum sampling time that embraces
all of the possible surrogate end points for
the uterotrophic assay. In addition, the accu-
rate quantification of protein/mRNA levels
adds a further level of complexity, which in
the case of mRNA changes will involve the
use of real-time polymerase chain reaction.
Set against these problems is the fact that
gravimetric analysis of the uterus sometimes
also yields conﬂicting or weak responses, as
illustrated by the results observed with the
nine mouse uterotrophic assays of BPA
reported by Tinwell et al. (17). 
Finally, the future use of cellular or mole-
cular markers will focus the potential differ-
ence between the no-observed-adverse-effect
level (NOAEL) of a chemical and its NOEL.
In time, it may be possible and necessary to
differentiate the expression of estrogen-regu-
lated genes associated with the eventual
appearance of an adverse effect from the
expression of those that merely give nonspe-
cific evidence of chemical exposure. In this
connection, the assumption that all estrogen-
dependent changes induced in the uterus by
a chemical form part of a continuous cascade,
ending in uterine growth, is challenged by
the observation that certain synthetic estro-
gens, but not estradiol, induce the expression
of lactoferrin in uterine epithelial cells of the
estrogen receptor (ER)-knockout mice
(20,21). This observation indicates an estro-
gen-signaling pathway in the mouse uterus
that is independent of both ERα, and ERβ
(20,21). Until such uncertainties are
resolved, I suggest that the gravimetric
uterotrophic assay should remain a reference
tier-1 assay for assessment of the estrogenic
activity of xenobiotic chemicals. The practi-
cality of the assay remains its primary
strength, and although estrogenic effects of a
different magnitude may be produced by
chemicals in tissues other than the uterus
[due to possession by the chemical of selec-
tive estrogen receptor modulating (SERM)
activity], it is interesting to note that ralox-
ifene, a SERM reported not to affect the
uterus (22), gives a positive uterotrophic
response (23). Nonetheless, all biological
end points, including the uterotrophic assay,
have intrinsic fragility, as evidenced by the
demonstration that changes in the nutri-
tional status of immature rodents can initiate
premature uterine growth via centrally medi-
ated mechanism (24).
Perhaps the greatest current need is for
agreement on criteria for concomitantly com-
paring the relative sensitivity of individual
assay end points. For example, although
Newbold et al. (25,26) recently concluded
that assessment of gland number and lactofer-
rin expression in the mouse uterus enhances
the sensitivity of the uterotrophic assay, it was
unclear about which of the data sets presented
were concomitantly determined and which
were mechanistically coupled (27). 
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